Últimas noticias sobre Solventum (NYSE:SOLV) Bolsa

Solventum

Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.

Solventum Corp

SOLVE

SOLVAC SA by SOLVAC SA

SOLVBL SOLUTIONS INC by SOLVBL SOLUTIONS INC.

SoLVBL Solutions Inc

SOLVAY BANK SOLVAY NY by Solvay Bank (NY)

Solvay Bank

Solvay SA

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 10 years by 7.08% on an annualized basis producing an average annual return of 17.97%. Currently, Primerica has a market capitalization of $9.18 billion. 
Buying $1000 In PRI: If an investor had bought $1000 of PRI stock 10 years ago, it would be worth $5,199.51 today based on a price of $275.22 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740499211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Primerica 10 Years Ago Would Be Worth This Much Today

DA Davidson analyst Brent Thielman maintains Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) with a Buy and maintains $85 price target.

Price Target

Analyst Ratings

PRIM

DA Davidson Maintains Buy on Primoris Services, Maintains $85 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Market Outperform and maintains $32 price target.

Reiteration

SMMT

Citizens Capital Markets Reiterates Market Outperform on Summit Therapeutics, Maintains $32 Price Target

Truist Securities analyst Peter Osterland maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Buy and lowers the price target from $168 to $166.

Truist Securities Maintains Buy on Westlake, Lowers Price Target to $166

DA Davidson analyst Michael Shlisky maintains Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) with a Buy and maintains $32 price target.

PLOW

DA Davidson Maintains Buy on Douglas Dynamics, Maintains $32 Price Target

Citizens Capital Markets analyst David Turkaly reiterates SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) with a Market Outperform and maintains $32 price target.

SIBN

Citizens Capital Markets Reiterates Market Outperform on SI-BONE, Maintains $32 Price Target

Truist Securities analyst Keith Hughes maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Buy and lowers the price target from $100 to $90.

TREX

Truist Securities Maintains Buy on Trex Co, Lowers Price Target to $90

Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) is set to release its fourth-quarter financial results after Tuesday's closing bell. Here's a look at what to <a href="https://www.benzinga.com/tech/25/02/43907447/lucid-awards-limited-edition-lucid-air-sapphire-with-lavender-finish-to-winner-of-saudi-cup-2025">expect in the report.&nbsp;</a>
What To Watch: Lucid reported record deliveries of 3,099 vehicles in the fourth quarter, up 79% year-over-year, due in part <a href="https://www.benzinga.com/news/25/02/43516605/lucid-deliveries-up-51-in-january-heres-how-many-gravity-suvs-sold-in-first-full-month">to the launch</a> of the Lucid Gravity SUV. Investors will be watching fiscal 2024&nbsp; production numbers which Lucid guided to approximately 9,000 vehicles in its third-quarter report.&nbsp;
Wall Street will be looking for improvements in the company's gross margin performance and updates on its cost reduction efforts and cash reserves as the company has yet to turn a profit.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/earnings/25/02/43929653/first-solar-q4-earnings-preview-sales-net-bookings-to-watch"> First Solar Q4 Earnings Preview: Sales, Net Bookings To Watch</a>&nbsp;
Benchmark analyst Mickey Legg recently initiated coverage on Lucid stock with a Buy rating and a $5 price target, according to Markets Insider. The analyst highlighted the company's strong cash reserves and product lineup and sees EV production in the U.S. ramping up in 2025.&nbsp;
Legg also noted that though President Donald Trump's plan to cut incentives may slow EV adoption, Lucid could gain market share as legacy automakers delay their shift to electric vehicles.
According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect the company to report quarterly losses of 25 cents per share on revenue of $214.22 million.&nbsp;
LCID Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Lucid Group shares are down 3.24% at $2.69 at the time of publication Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">Financial Crime Weekly: $1.4 Billion Ethereum Stolen In Largest Crypto Hack Ever, SEC Creates Cyber And Emerging Technologies Unit</a></li>
</ul>
Image: Shutterstock

Earnings

Previews

Tech

LCID

Lucid Q4 Earnings Preview: Production, Deliveries, Margins On Watch

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

Truist Securities analyst Samuel Brodovsky reiterates SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) with a Buy and raises the price target from $18 to $22.

Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $22

Macro Economic Events

Market Summary

Economics

General

$BTC

Benzinga Market Summary: S&P Falls On Continued Economic Concerns, Feb. Consumer Confidence Comes In Below Estimates, Oil And Bitcoin Move Lower

WIIM

Bank Of Montreal shares are trading higher after the company reported better-than-expected Q1 financial results.

Citizens Capital Markets analyst Greg Miller reiterates SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Market Outperform and maintains $250 price target.

SBAC

Citizens Capital Markets Reiterates Market Outperform on SBA Comms, Maintains $250 Price Target

Truist Securities analyst Patrick Scholes reiterates Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy and lowers the price target from $136 to $133.

Truist Securities Reiterates Buy on Ryman Hospitality Props, Lowers Price Target to $133

Oil is trading lower. The commodity may be under pressure amid President Trump's Russia-Ukraine policies as well as US economic concerns, which could affect demand outlook. Additionally, US crude inventories rose last week.

Dan&nbsp;Loeb‘s&nbsp;Third Point LLC, which has a varied mix of stock from across the sectors, did some major portfolio restructuring in the <a target="_blank" href="https://www.benzinga.com/topic/dan-loeb" rel="noreferrer noopener">last quarter of 2024</a>.
According to recent 13F filings,&nbsp;reflecting his holding as of Dec. 31, 2024, Loeb slashed a stake in the major Life Sciences Tools &amp; Services company Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">to </a>1,900,000 from 1,950,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">in </a>the third quarter of 2024, a decline of around 2.5%.
Notably, the investor has been cutting stake in Danaher in the last couple of quarters. Earlier, he held 2,050,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624004004/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">as </a>of second quarter of 2024 and 2,450,000 shares as <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514623004511/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">of </a>third quarter of 2023.
Instead, the investor acquired a stake in Danaher&#8217;s major peer Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), attaining 350,000 shares in the fourth quarter 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/02/43861240/repligens-q4-earnings-beat-2025-guidance-highlights-market-growth" rel="noreferrer noopener">Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook</a>
DHR Major Events:
<ul>
<li>In January, the company reported weaker-than-expected fourth-quarter earnings, with adjusted earnings per share of $2.14 missing the street view of $2.16 and sales of $6.54 billion (+2%), beating the analyst <a href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" target="_blank" rel="noreferrer noopener">consensus estimate of $6.42 billion</a>.</li>
<li>Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">core revenue for the full year of 2025</a>.</li>
<li>Following the earnings release, several analysts cut the price forecast on the stock, with Barclays analyst Luke Sergott lowering the price forecast from $275 to $240 and Wells Fargo analyst Brandon Couillard curtailing the price target from $280 to $240 and <a href="https://www.benzinga.com/25/01/43336758/danaher-analysts-cut-their-forecasts-after-downbeat-earnings" target="_blank" rel="noreferrer noopener">both maintaining an Equal-Weight</a>.</li>
<li>This month, Danaher raised quarterly dividend <a href="https://www.benzinga.com//node/43866316" target="_blank" rel="noreferrer noopener">per share from&nbsp;$0.27&nbsp;to&nbsp;$0.32</a>.</li>
</ul>
TMO Major Events:
<ul>
<li>Last month, the company reported fourth-quarter adjusted earnings per share of $6.10, beating the street view of $5.94 and sales of $11.395 billion (+5% year over year) outpaced the analyst <a href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" target="_blank" rel="noreferrer noopener">consensus estimate of $11.277 billion</a>.</li>
<li>Following the earnings release, several analysts raised the price forecast on the stock, with Morgan Stanley analyst Tejas Savant increasing the price target from&nbsp;$647&nbsp;to&nbsp;$678 and Wells Fargo analyst Brandon Couillard upped <a href="https://www.benzinga.com/quote/TMO/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from&nbsp;$660&nbsp;to&nbsp;$680</a>.</li>
<li>This month, Thermo Fisher Scientific raised its quarterly dividend<a href="https://www.benzinga.com//node/43830343" target="_blank" rel="noreferrer noopener"> from $0.39 to $0.43 per share</a>.</li>
<li>Thermo Fisher inked a 10-year VPPA with X-ELIO to enhance renewable energy access in pharmaceutical and healthcare supply chains through the Lorca solar project, set to launch <a href="https://www.benzinga.com/pressreleases/25/02/b43460138/thermo-fisher-scientific-accelerates-100-percent-renewable-electricity-goal-for-european-operation" target="_blank" rel="noreferrer noopener">in early 2026 with three industry partners</a>.</li>
</ul>
Year to date, Danaher shares declined around 10% while Thermo Fisher rose 0.66%, both underperforming the iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which gained about 5%&nbsp;over the same time frame.
Also, the companies top peers Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) fell roughly 0.3% and IQVIA Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) declined about 1.3% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43796723/dan-loebs-third-point-boosts-meta-holdings-now-a-top-4-position" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Third Point Boosts Meta Holdings, Now A Top 4 Position</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

ETFs

iShares Trust Dow Jones US Healthcare Sector Index Fund

Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor

Citizens Capital Markets analyst Karol Chmiel reiterates ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Market Outperform and maintains $20 price target.

Citizens Capital Markets Reiterates Market Outperform on ProAssurance, Maintains $20 Price Target

Citizens Capital Markets analyst Nicholas Jones reiterates Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) with a Market Outperform and maintains $4.5 price target.

OPAD

Citizens Capital Markets Reiterates Market Outperform on Offerpad Solutions, Maintains $4.5 Price Target

NRG Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) short percent of float has fallen 29.47% since its last report. The company recently reported that it has 6.30 million shares sold short, which is 4.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>NRG Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740498327_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NRG Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing NRG Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, NRG Energy's peer group average for short interest as a percentage of float is 2.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About NRG Energy?

Cogent Comms Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NYSE">CCOI</a>) short percent of float has fallen 8.3% since its last report. The company recently reported that it has 3.45 million shares sold short, which is 11.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cogent Comms Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740498322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cogent Comms Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cogent Comms Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cogent Comms Hldgs's peer group average for short interest as a percentage of float is 6.22%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CCOI

Peering Into Cogent Comms Hldgs's Recent Short Interest

Press Releases

Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance

Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment

Solventum to Participate in the Piper Sandler Healthcare Conference

The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

Trian Issues Open Letter to Solventum Shareholders

Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025

Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging

Management

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

SOLV

Align Tech

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Mizuho

Morgan Stanley

Piper Sandler

Stifel

Goldman Sachs

Solventum shares are trading higher after the company announced Thermo Fisher will acquire its purification and filtration business for $4.1 billion in cash.

Comments

Solventum

Noticias

Últimas noticias sobre Solventum (NYSE:SOLV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL